| Risk | Moderately High |
|---|---|
| Min SIP Amount | Not Supported |
| Expense Ratio | 1.40% |
| NAV | ₹9.24 (07 Aug 2020) |
|---|---|
| Fund Started | 10 Nov 2017 |
| Fund Size | ₹94 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Bharti Airtel Ltd. | Communication | Equity | 7.0% |
| ICICI Bank Ltd. | Financial | Equity | 5.2% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 5.1% |
| Larsen & Toubro Ltd. | Construction | Equity | 4.3% |
| National Thermal Power Corp. Ltd. | Energy | Equity | 3.8% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 3.8% |
| Cipla Ltd. | Healthcare | Equity | 3.8% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 3.8% |
| Petronet LNG Ltd. | Energy | Equity | 3.4% |
| State Bank of India | Financial | Equity | 3.1% |
Sundaram Value Fund Series IX Regular Growth is a Equity Mutual Fund Scheme launched by Sundaram Mutual Fund. This scheme was made available to investors on 10 Nov 2017. S Bharath is the Current Fund Manager of Sundaram Value Fund Series IX Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹94 Cr and the Latest NAV as of 07 Aug 2020 is ₹9.24.
The Sundaram Value Fund Series IX Regular Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
To provide long term capital growth by investing primarily in well-diversified portfolio of companies accumulated at a discount to its fair value after taking into consideration various factors such as earnings, Asset Value, free cash flow and dividend yield. However, there can be no assurance that the investment objective of the Scheme will be realized.